聚乙二醇干扰素α-2b联合利巴韦林治疗静脉药瘾者慢性丙型肝炎38例疗效观察

Observation on Peg-IFN alpha-2β Combined with Capsule Ribavirin in Treatment Drug Addicts with Chronic Hepatitis C

目的评价聚乙二醇干扰素α-2b联合利巴韦林治疗静脉药瘾者慢性丙型肝炎的病毒学应答。方法38例静脉药瘾者慢性丙型肝炎患者为治疗组,设同期就诊输血后慢性丙型肝炎患者37例为对照组,均予聚乙二醇干扰素α-2b(80μg/w)联合利巴韦林[10.6mg/(kg.d)]治疗48周,检测基线及治疗12周、48周时的血浆HCVRNA水平,治疗后随访24周,比较两组早期病毒学应答(EVR)率、治疗终点病毒学应答(ETVR)率和持续病毒学应答(SVR)率。结果治疗组和对照组EVR率、ETVR率、SVR率分别为44.74%、76.32%、63.16%和48.65%、75.68%、64.86%,组间比较,差异均无统计学意义(P>0.05)。结论静脉药瘾者慢性丙型肝炎用聚乙二醇干扰素α-2b联合利巴韦林治疗的病毒学应答与输血后慢性丙型肝炎人群相当,聚乙二醇干扰素α-2b联合利巴韦林是静脉药瘾者慢性丙型肝炎的有效治疗选择。

Objective To evaluate the efficacy of peg - IFN alpha - 2b combined with ribavirin in treatment of intravenous drug users （IVDU） with Chronic Hepatitis C. Methods 38 IVDUs with Chronic Hepatitis C were defined to treatment group and 37 patients with Chronic Hepatitis C related to transfusionem were derided into control group. All of the patients received peg - IFN alpha - 2h combined with ribavirin for 48 -week, and a 24 -week of follow- up were performed. HCV RNA was tested at the baseline, 12 -week postmanagement, 48 -week postmanagement, and 24 -week after completion of a full course, respectively. The early virological response（EVR） rate, end of treatment virological response（ETVR） rate, sustained virological response （SVR） rate was assessed, then to compare the difefences between the two group. Results The EVR rate, ETVR rate, SVR rate in treatment group was 44.74% ,76.32% ,63.16% respectively, accordingly the rate in control group was 48.65% ,75.68% ,64.86%. The diferences between the two group were not statistically significant（P 〉0.05）. Conclusions Compared with the patients with Chronic Hepatitis C related to transfusionem, the efficiency of peg -IFN alpha- 2h combined with rihavirin in treatment of IVDU with Chronic Hepatitis C was similar, and the therapy is a effective choice in treatment of IVDU with Chronic Hepatitis C.